Advertisement

Pharmacologic Issues in Treating Hypertension in CKD

  • Domenic A. Sica
    Correspondence
    Address correspondence to Domenic A. Sica, MD, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298-0160.
    Affiliations
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA
    Search for articles by this author
      Antihypertensive drugs are prescribed to patients with CKD to slow down the rate of loss of residual kidney function; to reduce proteinuria, when present; and to protect other target organs from damage that is mediated by elevated blood pressure (BP). In most patients, a diuretic and a renin system blocking drug, such as an angiotensin-converting enzyme inhibitor, angiotensin receptor antagonist, or an aldosterone receptor antagonist are used. Often, 3 or more drugs are needed to achieve BP goals. Many drugs are eliminated through the kidney and in some cases dosage reductions are advisable to avoid adverse effects from high levels of medication. This article will review the various classes of antihypertensive drugs used in the management of high BP in patients with CKD, with an emphasis on pitfalls that arise when kidney function is impaired.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sica D.
        • Carl D.
        Pathologic basis and treatment considerations in chronic kidney disease-related hypertension.
        Semin Nephrol. 2005; 25: 246-251
        • Lewis J.B.
        Blood pressure control in chronic kidney disease: is less really more?.
        J Am Soc Nephrol. 2010; 21: 1086-1092
        • Appel L.J.
        • Wright Jr., J.T.
        • Greene T.
        • et al.
        Intensive blood-pressure control in hypertensive chronic kidney disease.
        N Engl J Med. 2010; 363: 918-929
        • Kidney Disease Outcomes Quality Initiative (K/DOQI)
        K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
        Am J Kidney Dis. 2004; 43: S1-S290
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • Bakris G.L.
        • Weir M.R.
        • Shanifar S.
        • et al.
        Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
        Arch Intern Med. 2003; 163: 1555-1565
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860
        • Berl T.
        • Hunsicker L.G.
        • Lewis J.B.
        • et al.
        Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy.
        Ann Intern Med. 2003; 138: 542-549
        • Rahman M.
        • Pressel S.
        • Davis B.R.
        • et al.
        Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
        Ann Intern Med. 2006; 144: 172-180
        • Sica D.A.
        Metolazone and its role in edema management.
        Congest Heart Fail. 2003; 9: 100-105
        • Mitch W.E.
        • Wilcox C.S.
        Disorders of body fluids, sodium and potassium in chronic renal failure.
        Am J Med. 1982; 72: 536-550
        • Calhoun D.A.
        • Jones D.
        • Textor S.
        • et al.
        Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
        Hypertension. 2008; 51: 1403-1419
        • Sica D.A.
        The risks and benefits of aldosterone antagonists.
        Curr Heart Fail Rep. 2005; 2: 65-71
        • Santos J.
        • Planas R.
        • Pardo A.
        • et al.
        Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
        J Hepatol. 2003; 39: 187-192
        • Sica D.A.
        Eplerenone: a new aldosterone receptor antagonist: are the FDA’s restrictions appropriate.
        J Clin Hypertens (Greenwich). 2002; 4: 441-445
        • Sica D.A.
        Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not.
        Hypertension. 2009; 53: 749-750
        • Sica D.A.
        Kinetics of angiotensin converting enzyme inhibitors in renal failure.
        J Cardiovasc Pharmacol. 1992; 20: S13-S20
        • Haas M.
        • Leko-Mohr Z.
        • Erler C.
        • Mayer G.
        Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy.
        Am J Kidney Dis. 2002; 40: 458-463
        • Tobe S.W.
        • Dai M.O.
        Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy.
        Curr Hypertens Rep. 2009; 11: 345-353
        • Ruggenenti P.
        • Mise N.
        • Pisoni R.
        • et al.
        Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies.
        Circulation. 2003; 107: 586-592
        • Schoolwerth A.
        • Sica D.A.
        • Ballermann B.J.
        • Wilcox C.S.
        Renal considerations in angiotensin converting enzyme inhibitor therapy.
        Circulation. 2001; 104: 1985-1991
        • Sica D.A.
        Renal handling of angiotensin receptor blockers: clinical relevance.
        Curr Hypertens Rep. 2003; 5: 337-339
        • Bakris G.L.
        • Siomos M.
        • Richardson D.
        • et al.
        ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
        Kidney Int. 2000; 58: 2084-2092
        • Vaidyanathan S.
        • Bigler H.
        • Yeh C.
        • et al.
        Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
        Clin Pharmacokinet. 2007; 46: 661-675
        • Parving H.H.
        • Persson F.
        • Lewis J.B.
        • Lewis E.J.
        • Hollenberg N.K.
        • AVOID Study Investigators
        Aliskiren combined with losartan in type 2 diabetes and nephropathy.
        N Engl J Med. 2008; 358: 2433-2446
        • Sica D.A.
        • Gehr T.W.
        Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations.
        Curr Opin Nephrol Hypertens. 2003; 12: 123-131
        • Chrysant S.G.
        • Chrysant C.
        • Trus J.
        • Hitchcock A.
        Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide.
        Am J Hypertens. 1989; 2: 537-541
        • Sica D.A.
        Current concepts of pharmacotherapy in hypertension: combination calcium channel blocker therapy in the treatment of hypertension.
        J Clin Hypertens (Greenwich). 2001; 3: 322-327
        • Agodoa L.Y.
        • Appel L.
        • Bakris G.L.
        • et al.
        Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
        JAMA. 2001; 285: 2719-2728
        • Bakris G.L.
        • Weir M.R.
        • Secic M.
        • et al.
        Differential effects of calcium antagonist subclasses on markers of nephropathy progression.
        Kidney Int. 2004; 65: 1991-2002
        • Frishman W.H.
        • Alwarshetty M.
        Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.
        Clin Pharmacokinet. 2002; 41: 505-516
        • McCullough P.A.
        • Sandberg K.R.
        • Borzak S.
        • et al.
        Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease.
        Am Heart J. 2002; 144: 226-232
        • Bakris G.L.
        Role for beta-blockers in the management of diabetic kidney disease.
        Am J Hypertens. 2003; 16: 7S-12S
        • Schlaich M.P.
        • Socratous F.
        • Hennebry S.
        • et al.
        Sympathetic activation in chronic renal failure.
        J Am Soc Nephrol. 2009; 20: 933-939
        • Lowenthal D.T.
        • Affrime M.B.
        • Meyer A.
        • et al.
        Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function.
        Chest. 1983; 83: 386-390
        • Sica D.A.
        • Grubbs R.
        Transdermal clonidine: therapeutic considerations.
        J Clin Hypertens (Greenwich). 2005; 7: 558-562
        • Ross E.A.
        • Pittman T.B.
        • Koo L.C.
        Strategy for the treatment of noncompliant hypertensive hemodialysis patients.
        Int J Artif Organs. 2002; 25: 1061-1065
        • Byrd III, B.F.
        • Collins H.W.
        • Primm R.K.
        Risk factors for severe bradycardia during oral clonidine therapy for hypertension.
        Arch Intern Med. 1988; 148: 729-733
        • Black H.R.
        • Sollins J.S.
        • Garofalo J.L.
        The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
        Am J Hypertens. 2000; 13: 468-474
        • Yasuda G.
        • Hasegawa K.
        • Kuji T.
        • et al.
        Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
        Diabet Med. 2005; 22: 1394-1400
        • Mori Y.
        • Matsubara H.
        • Nose A.
        • et al.
        Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
        Hypertens Res. 2001; 24: 359-363
        • Bryson C.L.
        • Psaty B.M.
        A review of the adverse effects of peripheral alpha-1 antagonists in hypertension therapy.
        Curr Control Trials Cardiovasc Med. 2002; 3: 1-7